Context Therapeutics (CNTX) vs Seres Therapeutics (MCRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Context Therapeutics is the larger company by market cap ($27.8 million vs $27.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTX | MCRB |
|---|---|---|
| Share price | $0.3021 | $2.71 |
| Market cap | $27.76M | $27.21M |
| 1-day change | +1.04% | +3.00% |
| YTD return | -79.66% | — |
| 1-year return | -73.77% | — |
| EPS (TTM) | $-0.48 | $-2.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.62 | $29.98 |
| 52-week low | $0.295 | $2.42 |
| Distance from 52-week high | -91.65% | -90.96% |
| Analyst consensus | none | none |
| Avg. price target upside | +1234.00% | +527.56% |
| Average volume | 1.66M | 73.43K |
| Shares outstanding | 91.88M | 10.04M |
| Employees | 15 | 66 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Context Therapeutics
CNTX stock →Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Seres Therapeutics
MCRB stock →Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees
CNTX vs MCRB FAQ
Which is bigger, Context Therapeutics or Seres Therapeutics?
Context Therapeutics (CNTX) is larger, with a market capitalization of $27.76M compared with $27.21M for Seres Therapeutics (MCRB).
Are Context Therapeutics and Seres Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.